Oncogenes strike a balance between cellular growth and homeostasis

Seminars in Cell and Developmental Biology

Volumn 43, Issue , 2015, Pages 3-10

  Qiu, Bo ^a,b   Simon, M Celeste ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

AMPK; Autophagy; Cancer metabolism; ER stress; Hypoxia inducible factors; Stress response

Indexed keywords

HYPOXIA INDUCIBLE FACTOR; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; ENDOTHELIAL PAS DOMAIN-CONTAINING PROTEIN 1; HIF1A PROTEIN, HUMAN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 1; MULTIPROTEIN COMPLEX; MYC PROTEIN; MYC PROTEIN, HUMAN; PROTEIN P21; TARGET OF RAPAMYCIN KINASE;

ADAPTATION; AUTOPHAGY; CELL ENERGY; CELL GROWTH; CELL METABOLISM; CELL TRANSFORMATION; ENDOPLASMIC RETICULUM; ENDOPLASMIC RETICULUM MEMBRANE; ENDOPLASMIC RETICULUM STRESS; HOMEOSTASIS; HUMAN; KIDNEY CARCINOMA; LIPID METABOLISM; LIPOGENESIS; METABOLISM; ONCOGENE; PREVENTION; PROTEIN SYNTHESIS; REVIEW; STRESS; TUMOR MICROENVIRONMENT; CELL PROLIFERATION; ENERGY METABOLISM; GENETICS; MITOCHONDRION; NEOPLASM; OXIDATIVE STRESS; PATHOLOGY; PHYSIOLOGY;

AMP-ACTIVATED PROTEIN KINASES; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; ENDOPLASMIC RETICULUM; ENERGY METABOLISM; HOMEOSTASIS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LIPID METABOLISM; MITOCHONDRIA; MULTIPROTEIN COMPLEXES; NEOPLASMS; ONCOGENE PROTEIN P21(RAS); OXIDATIVE STRESS; PROTO-ONCOGENE PROTEINS C-MYC; TOR SERINE-THREONINE KINASES; TUMOR MICROENVIRONMENT;

EID: 84948085766     PISSN: 10849521     EISSN: 10963634     Source Type: Journal    
DOI: 10.1016/j.semcdb.2015.08.005     Document Type: Review

References (82)

1. Deberardinis R.J., Sayed N., Ditsworth D., Thompson C.B. Brick by brick: metabolism and tumor cell growth. Curr. Opin. Genet. Dev. 2008, 18:54-61.
2. Ward P.S., Thompson C.B. Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. Cancer Cell 2012, 21:297-308.
3. Barna M., Pusic A., Zollo O., Costa M., Kondrashov N., Rego E., et al. Suppression of Myc oncogenic activity by ribosomal protein haploinsufficiency. Nature 2008, 456:971-975.
4. Faller W.J., Jackson T.J., Knight J.R., Ridgway R.A., Jamieson T., Karim S.A., et al. mTORC1-mediated translational elongation limits intestinal tumour initiation and growth. Nature 2015, 517:497-500.
5. Sabharwal S.S., Schumacker P.T. Mitochondrial ROS in cancer: initiators, amplifiers or an Achilles' heel?. Nat. Rev. Cancer 2014, 14:709-721.
6. Laplante M., Sabatini D.M. mTOR signaling in growth control and disease. Cell 2012, 149:274-293.
7. Ben-Sahra I., Howell J.J., Asara J.M., Manning B.D. Stimulation of de novo pyrimidine synthesis by growth signaling through mTOR and S6K1. Science 2013, 339:1323-1328.
8. Robitaille A.M., Christen S., Shimobayashi M., Cornu M., Fava L.L., Moes S., et al. Quantitative phosphoproteomics reveal mTORC1 activates de novo pyrimidine synthesis. Science 2013, 339:1320-1323.
9. Chantranupong L., Wolfson R.L., Sabatini D.M. Nutrient-sensing mechanisms across evolution. Cell 2015, 161:67-83.
10. Tee A.R., Fingar D.C., Manning B.D., Kwiatkowski D.J., Cantley L.C., Blenis J. Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:13571-13576.
11. Zhang Y., Nicholatos J., Dreier J.R., Ricoult S.J., Widenmaier S.B., Hotamisligil G.S., et al. Coordinated regulation of protein synthesis and degradation by mTORC1. Nature 2014, 513:440-443.
12. White E. The role for autophagy in cancer. J. Clin. Investig. 2015, 125:42-46.
13. Kenific C.M., Debnath J. Cellular and metabolic functions for autophagy in cancer cells. Trends Cell Biol. 2015, 25:37-45.
14. Ozcan U., Ozcan L., Yilmaz E., Duvel K., Sahin M., Manning B.D., et al. Loss of the tuberous sclerosis complex tumor suppressors triggers the unfolded protein response to regulate insulin signaling and apoptosis. Mol. Cell 2008, 29:541-551.
15. Clarke H.J., Chambers J.E., Liniker E., Marciniak S.J. Endoplasmic reticulum stress in malignancy. Cancer Cell 2014, 25:563-573.
16. Walter P., Ron D. The unfolded protein response: from stress pathway to homeostatic regulation. Science 2011, 334:1081-1086.
17. Obeng E.A., Carlson L.M., Gutman D.M., Harrington W.J., Lee K.P., Boise L.H. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood 2006, 107:4907-4916.
18. Lee A.H., Scapa E.F., Cohen D.E., Glimcher L.H. Regulation of hepatic lipogenesis by the transcription factor XBP1. Science 2008, 320:1492-1496.
19. Fu S., Yang L., Li P., Hofmann O., Dicker L., Hide W., et al. Aberrant lipid metabolism disrupts calcium homeostasis causing liver endoplasmic reticulum stress in obesity. Nature 2011, 473:528-531.
20. Duvel K., Yecies J.L., Menon S., Raman P., Lipovsky A.I., Souza A.L., et al. Activation of a metabolic gene regulatory network downstream of mTOR complex 1. Mol. Cell 2010, 39:171-183.
21. Porstmann T., Santos C.R., Griffiths B., Cully M., Wu M., Leevers S., et al. SREBP activity is regulated by mTORC1 and contributes to Akt-dependent cell growth. Cell Metab. 2008, 8:224-236.
22. Peterson T.R., Sengupta S.S., Harris T.E., Carmack A.E., Kang S.A., Balderas E., et al. mTOR complex 1 regulates lipin 1 localization to control the SREBP pathway. Cell 2011, 146:408-420.
23. Young R.M., Ackerman D., Quinn Z.L., Mancuso A., Gruber M., Liu L., et al. Dysregulated mTORC1 renders cells critically dependent on desaturated lipids for survival under tumor-like stress. Genes Dev. 2013, 27:1115-1131.
24. Griffiths B., Lewis C.A., Bensaad K., Ros S., Zhang Q., Ferber E.C., et al. Sterol regulatory element binding protein-dependent regulation of lipid synthesis supports cell survival and tumor growth. Cancer Metab. 2013, 1:3.
25. Medvetz D., Priolo C., Henske E.P. Therapeutic targeting of cellular metabolism in cells with hyperactive mTORC1: a paradigm shift. Mol. Cancer Res. 2015, 13:3-8.
26. Dang C.V. MYC on the path to cancer. Cell 2012, 149:22-35.
27. Hart L.S., Cunningham J.T., Datta T., Dey S., Tameire F., Lehman S.L., et al. ER stress-mediated autophagy promotes Myc-dependent transformation and tumor growth. J. Clin. Investig. 2012, 122:4621-4634.
28. Shin J., He M., Liu Y., Paredes S., Villanova L., Brown K., et al. SIRT7 represses Myc activity to suppress ER stress and prevent fatty liver disease. Cell Rep. 2013, 5:654-665.
29. Carroll P.A., Diolaiti D., McFerrin L., Gu H., Djukovic D., Du J., et al. Deregulated Myc requires MondoA/Mlx for metabolic reprogramming and tumorigenesis. Cancer Cell 2015, 27:271-285.
30. Gao P., Tchernyshyov I., Chang T.C., Lee Y.S., Kita K., Ochi T., et al. c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature 2009, 458:762-765.
31. Dang C.V., Le A., Gao P. MYC-induced cancer cell energy metabolism and therapeutic opportunities. Clin. Cancer Res. 2009, 15:6479-6483.
32. Li F., Wang Y., Zeller K.I., Potter J.J., Wonsey D.R., O'Donnell K.A., et al. Myc stimulates nuclearly encoded mitochondrial genes and mitochondrial biogenesis. Mol. Cell. Biol. 2005, 25:6225-6234.
33. Kelly D.P., Scarpulla R.C. Transcriptional regulatory circuits controlling mitochondrial biogenesis and function. Genes Dev. 2004, 18:357-368.
34. Liu L., Ulbrich J., Muller J., Wustefeld T., Aeberhard L., Kress T.R., et al. Deregulated MYC expression induces dependence upon AMPK-related kinase 5. Nature 2012, 483:608-612.
35. Pylayeva-Gupta Y., Grabocka E., Bar-Sagi D. RAS oncogenes: weaving a tumorigenic web. Nat. Rev. Cancer 2011, 11:761-774.
36. Weinberg F., Hamanaka R., Wheaton W.W., Weinberg S., Joseph J., Lopez M., et al. Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:8788-8793.
37. Finkel T. Signal transduction by reactive oxygen species. J. Cell Biol. 2011, 194:7-15.
38. Fan J., Ye J., Kamphorst J.J., Shlomi T., Thompson C.B., Rabinowitz J.D. Quantitative flux analysis reveals folate-dependent NADPH production. Nature 2014, 510:298-302.
39. Ying H., Kimmelman A.C., Lyssiotis C.A., Hua S., Chu G.C., Fletcher-Sananikone E., et al. Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell 2012, 149:656-670.
40. Jiang P., Du W., Mancuso A., Wellen K.E., Yang X. Reciprocal regulation of p53 and malic enzymes modulates metabolism and senescence. Nature 2013, 493:689-693.
41. Guo J.Y., Karsli-Uzunbas G., Mathew R., Aisner S.C., Kamphorst J.J., Strohecker A.M., et al. Autophagy suppresses progression of K-ras-induced lung tumors to oncocytomas and maintains lipid homeostasis. Genes Dev. 2013, 27:1447-1461.
42. Yang S., Wang X., Contino G., Liesa M., Sahin E., Ying H., et al. Pancreatic cancers require autophagy for tumor growth. Genes Dev. 2011, 25:717-729.
43. Guo J.Y., Chen H.Y., Mathew R., Fan J., Strohecker A.M., Karsli-Uzunbas G., et al. Activated Ras requires autophagy to maintain oxidative metabolism and tumorigenesis. Genes Dev. 2011, 25:460-470.
44. Commisso C., Davidson S.M., Soydaner-Azeloglu R.G., Parker S.J., Kamphorst J.J., Hackett S., et al. Macropinocytosis of protein is an amino acid supply route in Ras-transformed cells. Nature 2013, 497:633-637.
45. Kamphorst J.J., Cross J.R., Fan J., de Stanchina E., Mathew R., White E.P., et al. Hypoxic and Ras-transformed cells support growth by scavenging unsaturated fatty acids from lysophospholipids. Proc. Natl. Acad. Sci. U.S.A. 2013, 110:8882-8887.
46. Majmundar A.J., Wong W.J., Simon M.C. Hypoxia-inducible factors and the response to hypoxic stress. Mol. Cell 2010, 40:294-309.
47. Semenza G.L. Hypoxia-inducible factors in physiology and medicine. Cell 2012, 148:399-408.
48. Kaelin W.G., Ratcliffe P.J. Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Mol. Cell 2008, 30:393-402.
49. Keith B., Johnson R.S., Simon M.C. HIF1alpha and HIF2alpha: sibling rivalry in hypoxic tumour growth and progression. Nat. Rev. Cancer 2012, 12:9-22.
50. Toschi A., Lee E., Gadir N., Ohh M., Foster D.A. Differential dependence of hypoxia-inducible factors 1 alpha and 2 alpha on mTORC1 and mTORC2. J. Biol. Chem. 2008, 283:34495-34499.
51. Blum R., Jacob-Hirsch J., Amariglio N., Rechavi G., Kloog Y. Ras inhibition in glioblastoma down-regulates hypoxia-inducible factor-1alpha, causing glycolysis shutdown and cell death. Cancer Res. 2005, 65:999-1006.
52. Chen C., Pore N., Behrooz A., Ismail-Beigi F., Maity A. Regulation of glut1 mRNA by hypoxia-inducible factor-1. Interaction between H-ras and hypoxia. J. Biol. Chem. 2001, 276:9519-9525.
53. Gao P., Zhang H., Dinavahi R., Li F., Xiang Y., Raman V., et al. HIF-dependent antitumorigenic effect of antioxidants in vivo. Cancer Cell 2007, 12:230-238.
54. Faubert B., Vincent E.E., Griss T., Samborska B., Izreig S., Svensson R.U., et al. Loss of the tumor suppressor LKB1 promotes metabolic reprogramming of cancer cells via HIF-1alpha. Proc. Natl. Acad. Sci. U.S.A. 2014, 111:2554-2559.
55. Sun R.C., Denko N.C. Hypoxic regulation of glutamine metabolism through HIF1 and SIAH2 supports lipid synthesis that is necessary for tumor growth. Cell Metab. 2014, 19:285-292.
56. Metallo C.M., Gameiro P.A., Bell E.L., Mattaini K.R., Yang J., Hiller K., et al. Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia. Nature 2012, 481:380-384.
57. Gameiro P.A., Yang J., Metelo A.M., Perez-Carro R., Baker R., Wang Z., et al. In vivo HIF-mediated reductive carboxylation is regulated by citrate levels and sensitizes VHL-deficient cells to glutamine deprivation. Cell Metab. 2013, 17:372-385.
58. Rankin E.B., Rha J., Selak M.A., Unger T.L., Keith B., Liu Q., et al. Hypoxia-inducible factor 2 regulates hepatic lipid metabolism. Mol. Cell. Biol. 2009, 29:4527-4538.
59. Walter K.M., Schonenberger M.J., Trotzmuller M., Horn M., Elsasser H.P., Moser A.B., et al. Hif-2alpha promotes degradation of Mammalian peroxisomes by selective autophagy. Cell Metab. 2014, 20:882-897.
60. Qiu B., Ackerman D., Sanchez D.J., Li B., Ochocki J.D., Grazioli A., et al. HIF-2alpha dependent lipid storage promotes endoplasmic reticulum homeostasis in clear cell renal cell carcinoma. Cancer Discov. 2015, 5(6):652-667.
61. Shen C., Beroukhim R., Schumacher S.E., Zhou J., Chang M., Signoretti S., et al. Genetic and functional studies implicate HIF1alpha as a 14q kidney cancer suppressor gene. Cancer Discov. 2011, 1:222-235.
62. Raval R.R., Lau K.W., Tran M.G., Sowter H.M., Mandriota S.J., Li J.L., et al. Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. Mol. Cell. Biol. 2005, 25:5675-5686.
63. Maranchie J.K., Vasselli J.R., Riss J., Bonifacino J.S., Linehan W.M., Klausner R.D. The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma. Cancer Cell 2002, 1:247-255.
64. Kondo K., Kim W.Y., Lechpammer M., Kaelin W.G. Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth. PLoS Biol. 2003, 1:E83.
65. Schodel J., Bardella C., Sciesielski L.K., Brown J.M., Pugh C.W., Buckle V., et al. Common genetic variants at the 11q13.3 renal cancer susceptibility locus influence binding of HIF to an enhancer of cyclin D1 expression. Nat. Genet. 2012, 44:420-425. S1-2.
66. Elorza A., Soro-Arnaiz I., Melendez-Rodriguez F., Rodriguez-Vaello V., Marsboom G., de Carcer G., et al. HIF2alpha acts as an mTORC1 activator through the amino acid carrier SLC7A5. Mol. Cell 2012, 48:681-691.
67. Gunaratnam L., Morley M., Franovic A., de Paulsen N., Mekhail K., Parolin D.A., et al. Hypoxia inducible factor activates the transforming growth factor-alpha/epidermal growth factor receptor growth stimulatory pathway in VHL(-/-) renal cell carcinoma cells. J. Biol. Chem. 2003, 278:44966-44974.
68. Walther T.C., Farese R.V. Lipid droplets and cellular lipid metabolism. Annu. Rev. Biochem. 2012, 81:687-714.
69. Wilfling F., Wang H., Haas J.T., Krahmer N., Gould T.J., Uchida A., et al. Triacylglycerol synthesis enzymes mediate lipid droplet growth by relocalizing from the ER to lipid droplets. Dev. Cell 2013, 24:384-399.
70. Haddad A.Q., Kapur P., Singla N., Raman J.D., Then M.T., Nuhn P., et al. Validation of mammalian target of rapamycin biomarker panel in patients with clear cell renal cell carcinoma. Cancer 2014, 121(1):43-50.
71. Faubert B., Vincent E.E., Poffenberger M.C., Jones R.G. The AMP-activated protein kinase (AMPK) and cancer: many faces of a metabolic regulator. Cancer Lett. 2015, 356:165-170.
72. Hardie D.G., Ross F.A., Hawley S.A. AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nat. Rev. Mol. Cell Biol. 2012, 13:251-262.
73. Ruggero D. Translational control in cancer etiology. Cold Spring Harb. Perspect. Biol. 2013, 5(2):5.
74. Browne G.J., Finn S.G., Proud C.G. Stimulation of the AMP-activated protein kinase leads to activation of eukaryotic elongation factor 2 kinase and to its phosphorylation at a novel site, serine 398. J. Biol. Chem. 2004, 279:12220-12231.
75. Horman S., Browne G., Krause U., Patel J., Vertommen D., Bertrand L., et al. Activation of AMP-activated protein kinase leads to the phosphorylation of elongation factor 2 and an inhibition of protein synthesis. Curr. Biol. 2002, 12:1419-1423.
76. Leprivier G., Remke M., Rotblat B., Dubuc A., Mateo A.R., Kool M., et al. The eEF2 kinase confers resistance to nutrient deprivation by blocking translation elongation. Cell 2013, 153:1064-1079.
77. Tennakoon J.B., Shi Y., Han J.J., Tsouko E., White M.A., Burns A.R., et al. Androgens regulate prostate cancer cell growth via an AMPK-PGC-1alpha-mediated metabolic switch. Oncogene 2014, 33:5251-5261.
78. Yan M., Gingras M.C., Dunlop E.A., Nouet Y., Dupuy F., Jalali Z., et al. The tumor suppressor folliculin regulates AMPK-dependent metabolic transformation. J. Clin. Investig. 2014, 124:2640-2650.
79. Masson N., Singleton R.S., Sekirnik R., Trudgian D.C., Ambrose L.J., Miranda M.X., et al. The FIH hydroxylase is a cellular peroxide sensor that modulates HIF transcriptional activity. EMBO Rep. 2012, 13:251-257.
80. Faubert B., Boily G., Izreig S., Griss T., Samborska B., Dong Z., et al. AMPK is a negative regulator of the Warburg effect and suppresses tumor growth in vivo. Cell Metab. 2013, 17:113-124.
81. Atkins C., Liu Q., Minthorn E., Zhang S.Y., Figueroa D.J., Moss K., et al. Characterization of a novel PERK kinase inhibitor with antitumor and antiangiogenic activity. Cancer Res. 2013, 73:1993-2002.
82. Gao Y., Sartori D.J., Li C., Yu Q.C., Kushner J.A., Simon M.C., et al. PERK is required in the adult pancreas and is essential for maintenance of glucose homeostasis. Mol. Cell. Biol. 2012, 32:5129-5139.